CGM097

CGM097 is an orally bioavailable small molecule inhibitor targeting the interaction between the human homolog of double minute 2 (HDM2, also known as MDM2) and the tumor suppressor protein p53. By inhibiting HDM2, which is a negative regulator of p53, CGM097 prevents HDM2 from binding to and promoting the degradation of p53. This leads to restoration of p53 signaling and induction of apoptosis in tumor cells with wild-type p53. The drug has demonstrated potential antineoplastic activity and has been investigated for its ability to reverse multidrug resistance mediated by ABCB1 transporters in cancer cells. Developed by Novartis, it reached phase 1 clinical trials for advanced malignant solid neoplasms[1][3][5][7][8].

Other names

1313363-54-0